The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin

被引:21
|
作者
Yamaguchi, Tetsuo [1 ]
Konishi, Hiroe [1 ,2 ]
Aoki, Kotaro [1 ]
Ishii, Yoshikazu [1 ]
Chono, Koji [3 ]
Tateda, Kazuhiro [1 ]
机构
[1] Toho Univ, Sch Med, Dept Microbiol & Infect Dis, Tokyo, Japan
[2] Toho Univ, Grad Sch Med, Div Pediat, Tokyo, Japan
[3] Astellas Pharma Inc, Res Portfolio Planning Drug Discovery & Res, Tsukuba, Ibaraki, Japan
关键词
16S rRNA; Clostridioides difficile; Fidaxomicin; Microbiota; RIBOTYPE; 027; MOUSE MODEL; INFECTION; LACTOFERRIN; STRAIN; SUSCEPTIBILITY; EPIDEMIOLOGY; RECURRENCE; PREVENTION; OUTCOMES;
D O I
10.1016/j.jiac.2019.12.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To investigate the effect of vancomycin and fidaxomicin on the diversity of intestinal microbiota in a mouse model of Clostridioides difficile infection. Methods: Mice were divided into 11 models (4 mice per model): 6 uninoculated models and 5 models inoculated with C. difficile BI/NAP1/027. Inoculated models were prepared using intraperitoneal clindamycin followed by inoculation with C. difficile BI/NAP1/027. Uninoculated and C. difficile-inoculated mice received 2 or 7 days' vancomycin or fidaxomicin. Clostridium butyricum MIYAIRI 588 probiotic and lactoferrin prebiotic were administered for 10 days to uninoculated mice. Intestinal microbiome composition was investigated by sequence analyses of bacterial 16S rRNA genes from faeces, and microbiota diversity estimated. Results: In uninoculated, untreated ('normal') mice, Clostridia (57.8%) and Bacteroidia (32.4%) accounted for the largest proportions of gut microbiota. The proportion of Clostridia was numerically reduced in C. difficile-inoculated versus normal mice. Administration of vancomycin to C. difficile-inoculated mice reduced the proportions of Bacteroidia and Clostridia, and increased that of Proteobacteria. Administration of fidaxomicin to C. difficile-inoculated mice reduced the proportion of Clostridia to a lesser extent, but increased that of Bacteroidia. Microbiota diversity was lower in C. difficile-inoculated versus normal mice (164.5 versus 349.1 operational taxonomic units (OTUs), respectively); treatment of C. difficile-inoculated mice with 7 days' vancomycin reduced diversity to a greater extent than did 7 days' fidaxomicin treatment (26.2 versus 134.2 OTUs, respectively). Conclusions: Both C. difficile inoculation and treatment with vancomycin or fidaxomicin reduced microbiota diversity; however, dysbiosis associated with fidaxomicin was milder than with vancomycin. (c) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:483 / 491
页数:9
相关论文
共 50 条
  • [31] Factors Influencing Time to Resolution of Diarrhea in Patients with Clostridium difficile Infection Treated with Fidaxomicin or Vancomycin.
    Gerding, D.
    Crook, D.
    Miller, M.
    Louie, T.
    Cornely, O.
    Peto, T.
    Gorbach, S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 : S144 - S145
  • [32] Quantitative characterization of Clostridioides difficile population in the gut microbiome of patients with C. difficile infection and their association with clinical factors
    Jieun Kim
    Youna Cho
    Mi-Ran Seo
    Mi Hyun Bae
    Bongyoung Kim
    Mina Rho
    Hyunjoo Pai
    Scientific Reports, 10
  • [33] Quantitative characterization of Clostridioides difficile population in the gut microbiome of patients with C. difficile infection and their association with clinical factors
    Kim, Jieun
    Cho, Youna
    Seo, Mi-Ran
    Bae, Mi Hyun
    Kim, Bongyoung
    Rho, Mina
    Pai, Hyunjoo
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [34] LONGITUDINAL EVALUATION OF GUT MICROBIOME AFTER FECAL MICROBIOTA TRANSPLANTATION FOR ERADICATING CLOSTRIDIOIDES DIFFICILE INFECTION
    Porcari, S.
    Karcher, N.
    Puncochar, M.
    Colomer, Valles M.
    Quaranta, G.
    Bibbo, S.
    De Giorgi, S.
    Masucci, L.
    Sanguinetti, M.
    Gasbarrini, A.
    Cammarota, G.
    Segata, N.
    Ianiro, G.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 : S142 - S143
  • [35] Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience
    Pettit, Natasha N.
    Lew, Alison K.
    Nguyen, Cynthia T.
    Bell, Elizabeth
    Lehmann, Christopher J.
    Pisano, Jennifer
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2024, 45 (11) : 1286 - 1292
  • [36] Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
    Nerandzic, Michelle M.
    Mullane, Kathleen
    Miller, Mark A.
    Babakhani, Farah
    Donskey, Curtis J.
    CLINICAL INFECTIOUS DISEASES, 2012, 55 : S121 - S126
  • [37] Gut microbiome changes in mouse, Mongolian gerbil, and hamster models following Clostridioides difficile challenge
    Wan, Shuangshuang
    You, Peijun
    Shi, Qikai
    Hu, Hui
    Zhang, Lu
    Chen, Leyang
    Wu, Ziyi
    Lin, Shan
    Song, Xiaojun
    Luo, Yongneng
    Wang, Yaxuan
    Ju, Feng
    Jin, Dazhi
    Chen, Yu
    FRONTIERS IN MICROBIOLOGY, 2024, 15
  • [38] Akkermansia muciniphila Ameliorates Clostridioides difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites
    Wu, Zhengjie
    Xu, Qiaomai
    Gu, Silan
    Chen, Yunbo
    Lv, Longxian
    Zheng, Beiwen
    Wang, Qiangqiang
    Wang, Kaicen
    Wang, Shuting
    Xia, Jiafeng
    Yang, Liya
    Bian, Xiaoyuan
    Jiang, Xianwan
    Zheng, Lisi
    Li, Lanjuan
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [39] Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models
    Tashiro, Sho
    Taguchi, Kazuaki
    Enoki, Yuki
    Matsumoto, Kazuaki
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (05) : 616 - 622
  • [40] Modulation of Lactobacillus rhamnosus GG on the gut microbiota and metabolism in mice with Clostridioides difficile infection
    Wu, Zhengjie
    Xu, Qiaomai
    Gu, Silan
    Wang, Qiangqiang
    Chen, Yunbo
    Lv, Longxian
    Zheng, Beiwen
    Wang, Kaicen
    Wang, Shuting
    Xia, Jiafeng
    Li, Lanjuan
    FOOD & FUNCTION, 2022, 13 (10) : 5667 - 5679